Skip to main content
. 2020 Dec 17;5(2):251–260. doi: 10.1007/s41669-020-00245-4

Table 3.

Deterministic results

Costs (£) Total LYG QALY Incremental cost (£) Incremental QALY Incremental cost per QALY gained (£/QALY)
Squamous
 Nivolumab 46,711 2.55 1.39
 Docetaxel 15,430 1.06 0.51 31,281 0.88 35,657
Non-squamous
 Nivolumab 47,569 2.53 1.54
 Docetaxel 19,209 1.30 0.81 28,360 0.73 38,703

LYG life-year gained, QALY quality-adjusted life-year